Catalase is a key antioxidant enzyme and has been implicated in many pathophysiological processes of human diseases. In a previous study, we developed a yeast-based expression system for recombinant human catalase (rhCAT), and proved its therapeutic effects for treating H1N1 virus-induced pneumonia. However, the preparation of rhCAT was insufficient for further research applications. Here, we describe a much more convenient construction strategy for rhCAT based on the Pichia pastoris GS115 strain in a 14 L bioreactor. Quantitative-PCR, Western blotting, and activity assay were used to demonstrate the stable and efficient high-level expression (1500 U/mL; 77% recovery) achieved by this newly developed simple two-step purification procedure. The rhCAT synthesized by this new procedure was applied to an H1N1-infected mouse model (doses of 50 and 100 kU/mice/day) to assess its capabilities for inducing immunomodulatory effects. The results showed that the rhCAT could restore the impaired phagocytosis, alleviate the induced reductions in spleen and thymus organ weights, and markedly reduce the lung tissue viral load, all in a dose-dependent manner. Thus, this study provides not only a simple method for large-scale preparation of active rhCAT, but also in vivo evidence of the recombinant protein's immunomodulatory activity which may have clinical applications in treating H1N1 or other viral infections. (C) 2013 Published by Elsevier Ltd.